RecruitingPhase 1NCT07776626
Renal
Primary hyperoxaluria type 1
12
studies recruiting now
as of 7 Sept 2026
54
studies registered in total
as of 7 Sept 2026
6
countries with a recruiting site
as of 7 Sept 2026
20 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07681271
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
RecruitingPhase 2NCT07587021
Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)
RecruitingNCT02780297
Prospective Research Rare Kidney Stones (ProRKS)
RecruitingNCT02026388
Rare Kidney Stone Consortium Biobank
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Primary hyperoxaluria type 1 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Primary hyperoxaluria type 1
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (AGXT).
Treatments being studied
2 approved treatments and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: NedosiranApproved: Lumasiran Sodium (Oxlumo)
Phase 3Lumasiran
Phase 2Pyridoxine (Pyridoxine component of vitaped)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).